Meeting
2017 Gastrointestinal Cancers Symposium
Safety and efficacy of accelerated hypofractionation and stereotactic body radiotherapy for hepatocellular carcinoma in the setting of advanced liver dysfunction.
Authors
Nima Nabavizadeh
Oregon Health & Science University, Portland, OR
Nima Nabavizadeh , Joseph Waller , Robert Fain III, Yiyi Chen , Catherine Degnin , David Elliott , Brandon T Mullins , Ishan Patel , Brandon Alan Dyer , Willscott E Naugler , Khashayar Farsad , James Tanyi , Martin Fuss , Charles R. Thomas Jr., Arthur Hung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 403)
DOI
10.1200/JCO.2017.35.4_suppl.403
Abstract #
403
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Stereotactic body radiotherapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) versus TACE and TKIs alone for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT): A randomized controlled trial.
First Author: Jiayu Duan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
First Author: Timothy J Brown
Poster
2018 Gastrointestinal Cancers Symposium
A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC).
First Author: Kim Anna Reiss
Poster
2014 Gastrointestinal Cancers Symposium
Collective analysis of efficacy and safety of patients with advanced hepatocellular carcinoma (HCC) enrolled into early-phase clinical trials.
First Author: Vinu Madhusudanannair